CEL-SCI Corporation (CVM)
NYSEAMERICAN: CVM · Real-Time Price · USD
0.828
-0.042 (-4.89%)
At close: Nov 4, 2024, 4:00 PM
0.818
-0.010 (-1.21%)
After-hours: Nov 4, 2024, 6:07 PM EST
CEL-SCI Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
50.89M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Fortress Biotech | 82.62M |
| Champions Oncology | 51.66M |
| Cytosorbents | 37.16M |
| Qilian International Holding Group | 29.87M |
| Affimed | 7.96M |
| Kezar Life Sciences | 7.00M |
| Pheton Holdings | 572.29K |
| Actinium Pharmaceuticals | 81.00K |
CVM News
- 13 days ago - FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients - Business Wire
- 4 weeks ago - CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer - Business Wire
- 7 weeks ago - CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation - Business Wire
- 7 weeks ago - CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress - Business Wire
- 2 months ago - The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance - Business Wire
- 2 months ago - CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results - Business Wire
- 3 months ago - CEL-SCI Announces Closing of $10.8 Million Offering - Business Wire
- 3 months ago - CEL-SCI Announces Pricing of $10.8 Million Offering - Business Wire